08:00 , Feb 26, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Nuclear receptor subfamily 0 group B member 2 (NR0B2); NLR family pyrin domain containing 3 (NLRP3; NALP3; CIAS1)

Endocrine/metabolic disease INDICATION: Hyperuricemia / gout; renal damage In vitro and mouse studies suggest promoting NR0B2 activity could help treat NLRP3 inflammasome-driven gout and kidney damage. In in vitro assays, NRB02 bound to NLRP3 to negatively regulate...
07:00 , Jul 21, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Various

Indication Target/marker/pathway Summary Licensing status Publication and contact information Various Inflammation; sepsis Nuclear receptor subfamily 0 group B member 2 (NR0B2; SHP) Mouse and cell culture studies...